Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap

Int J Tuberc Lung Dis. 2016 Jul;20(7):866-9. doi: 10.5588/ijtld.16.0034.


Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Antibiotics, Antitubercular / therapeutic use*
  • Biomedical Research / methods*
  • Drug Resistance, Bacterial*
  • Evidence-Based Medicine
  • Humans
  • Microbial Sensitivity Tests
  • Predictive Value of Tests
  • Professional Practice Gaps / methods*
  • Randomized Controlled Trials as Topic
  • Rifampin / therapeutic use*
  • Tuberculosis / diagnosis
  • Tuberculosis / drug therapy*
  • Tuberculosis / microbiology


  • Antibiotics, Antitubercular
  • Rifampin